The establishment of a global headquarters in Miami indicates InspireMD's commitment to expanding its operations in the U.S. market. This strategic move is likely to positively impact the company's stock as it prepares for the potential launch of its CGuard Prime carotid stent system in 2025, subject to regulatory approval. The anticipation of this product launch could drive investor interest and optimism.